Rapid-throughput bioprinting company Allegro 3D, a spin-off from the University of California San Diego (UCSD), was awarded nearly $1 million in grant funding this spring to develop a next-generation digital light processing (DLP)-based 3D bioprinter, commercialized under the name Stemaker, for printing in-vitro tissue models at the industrial scale. Now, the company is partnering with regenerative medicine startup Humabiologics to use human bioinks and develop tissue models for drug screening, cell culture, regenerative medicine, and therapeutics applications.
Humabiologics, which specializes in human-derived biomaterials, and Allegro 3D are both focused on using biomaterials and bioprinting technology to advance human healthcare. By working together and combining Allegro 3D’s fast, advanced DLP bioprinter—capable of direct printing in multiwell plates—with Humabiologics’ human bioinks, the two will speed up the high-throughout additive manufacturing of advanced human tissues and enable solutions that can improve the accuracy and efficiency of drug discovery, help create patient-specific therapies, and develop predictive disease models.
“Allegro 3D aspires to accelerate precision medicine with our rapid high-throughput bioprinters and a wide selection of bioinks. By partnering with Humabiologics, we are proud to be the first bioprinting company to provide total solutions for manufacturing clinically-relevant human tissues with human-derived biomaterials,” stated Allegro 3D’s CEO and Co-Founder Dr. Wei Zhu.
According to Allegro 3D, its STEMAKER is one of the fastest, most high-resolution bioprinters in the industry, with the ability to print live tissue constructs for screening and high-throughput assays that feature complex and intricate microscopic features, like vascularized human liver tissues. In fact, the company states that the DLP-based STEMAKER system can fabricate physiologically relevant tissue samples in a matter of seconds…talk about rapid.
Take this capability of quickly printing tissue models directly in multiwell plates and pair it with the affordable, high-quality human-derived biomaterials that Humabiologics creates and commercializes for bioprinting, cell therapy, drug screening, and tissue and disease modeling, and you’ve got quite the combination.
“We are excited to partner with Allegro 3D to provide clinically-relevant human-derived biomaterials that allow for fabricating human tissue models for rapid drug screening. Our off-the-shelf human bioinks complementing Allegro 3D’s transformative bioprinting technology and we look forward to develop other bioink formulas through our partnership to support researchers who are looking for reliable alternatives to animal testing for drug discovery,” said Dr. Mohammad Albanna, the CEO and Founder of Humabiologics.
Together, the two companies have demonstrated that human-derived bioinks made on the STEMAKER platform feature excellent printability, as well as biocompatibility, and can help increase the efficiency of the drug discovery process, along with decreasing the use of animal testing, which is always a good thing.
You can order these new bioinks on the Allegro 3D website.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
3D Printing News Briefs, December 3, 2022: Degradable Polymers & 3D Printed Trophies
We’re starting with some more formnext news in today’s 3D Printing News Briefs, as the Foundry Lab debuted its microwave technology for quicker, cheaper metal casting at the trade show....
Women in 3D Printing Introduces Advisory Board of AM Alums
As Women in 3D Printing (Wi3DP) continues to grow at a rapid pace, the organization is entering a new phase of evolution. This year, it made the enormous step of...
3D Printing Webinar and Event Roundup: October 9, 2022
We’ve got loads of things to tell you about in this week’s roundup! There are multiple events, both in-person and virtual, as well as numerous webinars on a variety of...
Mobility | Medical goes Additive Announces MGA Annual Meeting & Women in AM Summit 2022
Mobility goes Additive e.V. was founded in 2016 by companies such as the German Railway, Deutsche Bahn, one of the largest railway suppliers Siemens Mobility, and EOS, a globally renowned...